Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LIGHTRAY Extension open-label study of sotatercept in pulmonary arterial hypertension
MOH_2025-05-13_014086Phase 2Not yet recruiting
- Sponsor
- Merck & Co.
- Start
- Apr 2025
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sotatercept in pulmonary arterial hypertension (PAH), sponsored by Merck & Co. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
sotatercept
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on MOH_2025-05-13_014086.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2025-05-13_014086.